Now NICE Recommended1

Early breast cancer (eBC): Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy*2

.

Metastatic breast cancer (mBC): Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:2
• Received prior therapy for locally advanced or metastatic disease, or
• Developed disease recurrence during or within 6 months of completing adjuvant therapy

View the effect that Kadcyla had on outcomes in early and metastatic patients

eBC (adjuvant)

mBC

Mechanism of Action

Learn about the safety profile of Kadcyla in early and metastatic patients and how to manage adverse events

Across indications

eBC (adjuvant) safety & management

mBC safety & management

See practical guidance on how to dose and administer Kadcyla in the early and metastatic settings

Posology & Modifications

Preparation & administration

Duration of treatment

View a range of practical and educational resources

CPD® accredited learning

Downloadable presentation slides

Downloadable booklet

 

Access guidance

Early breast cancer (eBC) (adjuvant)

National Institute for Health and Care Excellence (NICE) recommendation - NEW

  • Kadcyla is recommended, within its marketing authorisation, as an option for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy*1

Metastatic breast cancer (mBC)

NICE recommendation

  • Kadcyla is recommended, within its marketing authorisation, as an option for treating HER2‑positive, unresectable, locally advanced or metastatic breast cancer in adults who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for locally advanced or metastatic disease or developed disease recurrence during or within 6 months of completing adjuvant therapy*3

Scottish Medicines Consortium recommendation

  • Kadcyla is accepted for use within NHS Scotland as a single agent, for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:4
    • Received prior therapy for locally advanced or metastatic disease, or
    • Developed disease recurrence during or within 6 months of completing adjuvant therapy

NICE, National Institute for Health and Care Excellence.


*NICE guidance is prepared for the NHS in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of it's content in this publication. Kadcyla is recommended only if the company provides it according to the commercial agreement.

References:

  1. National Institute for Health and Care Excellence. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA10468). May 2020.
  2. Kadcyla Summary of Product Characteristics.
  3. National Institute for Health and Care Excellence. Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458). November 2017.
  4. Scottish Medicines Consortium. SMC990/14. April 2017.

M-GB-00000738
Date of preparation: August 2020.